Inotuzumab Ozogamicin Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 1 mg
Reference Brands: Besponsa (USA/LATAM)
Category:
Oncology Cancer Care
Inotuzumab Ozogamicin is available in Injection
and strengths such as 1 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Inotuzumab Ozogamicin is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Inotuzumab Ozogamicin can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Inotuzumab ozogamicin is a targeted anticancer therapy classified as a monoclonal antibody–drug conjugate (ADC) used primarily for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The medicine combines a humanized monoclonal antibody that specifically targets the CD22 antigen found on malignant B cells with a potent cytotoxic agent called calicheamicin. Once the drug binds to CD22-positive leukemia cells, it is internalized into the cell, where the cytotoxic component is released to damage DNA and trigger cell death. This targeted approach helps deliver the chemotherapy directly to cancer cells while limiting exposure to normal tissues.
Inotuzumab ozogamicin has shown significant effectiveness in patients who have not responded well to previous treatments or whose disease has returned after therapy. It can help achieve remission and may serve as a bridge to stem cell transplantation in eligible patients. However, treatment requires careful monitoring because the drug can cause side effects, including low blood cell counts, infections, and liver-related complications. One of the most important risks associated with this therapy is sinusoidal obstruction syndrome, a serious liver condition that can occur during or after treatment. Due to these potential risks, therapy is typically managed by oncology specialists with regular clinical and laboratory monitoring to ensure patient safety and treatment effectiveness.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing